- Home
- BIRK vs EXEL Comparison
BIRK vs EXEL Comparison
Compare BIRK & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRK
- EXEL
- Stock Information
- Founded
- BIRK 1774
- EXEL 1994
- Country
- BIRK United Kingdom
- EXEL United States
- Employees
- BIRK N/A
- EXEL 1310
- Industry
- BIRK
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIRK
- EXEL Health Care
- Exchange
- BIRK Nasdaq
- EXEL Nasdaq
- Market Cap
- BIRK 9.4B
- EXEL 10.4B
- IPO Year
- BIRK 2023
- EXEL 2000
- Fundamental
- Price
- BIRK $58.96
- EXEL $36.43
- Analyst Decision
- BIRK Strong Buy
- EXEL Buy
- Analyst Count
- BIRK 15
- EXEL 17
- Target Price
- BIRK $67.27
- EXEL $35.50
- AVG Volume (30 Days)
- BIRK 1.2M
- EXEL 2.4M
- Earning Date
- BIRK 02-20-2025
- EXEL 02-04-2025
- Dividend Yield
- BIRK N/A
- EXEL N/A
- EPS Growth
- BIRK 148.78
- EXEL 441.02
- EPS
- BIRK 1.14
- EXEL 1.55
- Revenue
- BIRK $2,012,815,078.00
- EXEL $2,081,598,000.00
- Revenue This Year
- BIRK $20.02
- EXEL $20.53
- Revenue Next Year
- BIRK $17.04
- EXEL $0.95
- P/E Ratio
- BIRK $51.83
- EXEL $23.54
- Revenue Growth
- BIRK 20.96
- EXEL 17.31
- 52 Week Low
- BIRK $41.00
- EXEL $20.02
- 52 Week High
- BIRK $64.78
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- BIRK 60.70
- EXEL 59.74
- Support Level
- BIRK $55.02
- EXEL $33.05
- Resistance Level
- BIRK $60.62
- EXEL $37.59
- Average True Range (ATR)
- BIRK 1.86
- EXEL 1.02
- MACD
- BIRK -0.13
- EXEL 0.26
- Stochastic Oscillator
- BIRK 70.36
- EXEL 74.45
About BIRK Birkenstock Holding plc
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. The company operates in four operating segments based on its regional hubs: Americas, Europe and APMA (Asia Pacific, Middle East and Africa). The company sells its products through two main channels: business-to-business (B2B) and direct-to-consumer (DTC).
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.